BEVERLY, Mass., July 14, 2021 (GLOBE NEWSWIRE) – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company“), a molecular diagnostics company developing a fully automated rapid pathogen detection system, today announced its strategic relationship with Wolf Greenfield, an intellectual property (IP) law firm specializing in patents, license and royalty transactions, post-grant procedures, and trademarks and copyrights.
Dr Jack Regan, CEO and Founder of LexaGene, said, “As LexaGene continues to grow, it is important not only to protect, but also to maintain and develop the company’s intellectual property assets. I am very pleased to be able to rely on Wolf Greenfield’s nationally recognized expertise for all of our strategic intellectual property and licensing needs going forward. “
“Adding Wolf Greenfield to our team will be important as we continue to expand our patent portfolio,” continued Dr. Regan. “And by combining the strengths of Wolf Greenfield for intellectual property law and licensing, Latham and Watkins for securities law, gives us the capabilities of two of the most respected law firms in the United States in their respective fields, as we continue to achieve our growth goals.
The addition of Wolf Greenfield to its representative portfolio strengthens LexaGene’s positioning towards eventually register common shares in the Nasdaq capital market.
The company also announced that Dr. Regan will be speaking at the “Access to Giving” investor conference on Thursday, July 15. Access to Giving is a one-of-a-kind virtual investor conference, where mega-cap micro-capitalization companies will have the opportunity to present their company’s vision and participate in meetings with qualified investors, all for the benefit of from a range of associations. To register or to find out more visit, https://www.accesstogiving.com/. To listen to LexaGene’s presentation, register here: https://www.webcaster4.com/Webcast/Page/2744/41999. The audio recording will be posted on the LexaGene website at a later date.
On behalf of the board of directors
Dr Jack Regan
Managing Director & Chairman
About Wolf Greenfield
For nearly a century, Wolf Greenfield has helped clients protect their most valuable intellectual property. With more than 150 legal professionals based in Boston and New York, the firm offers a full range of intellectual property services, including patent lawsuits and litigation; post-grant procedures, including IPRs; strategic advice and advice; Licence; intellectual property and due diligence audits; trademark and copyright lawsuits and disputes; and other issues related to the commercialization of intellectual property.
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostic company that develops molecular diagnostic systems for the detection of pathogens and genetic testing for other molecular markers for rapid on-site testing in veterinary diagnostics, food safety and for use on open access markets such as clinical research, agricultural testing and biodefense. End users simply need to take a sample, load it onto the instrument with a sample preparation cartridge, enter the sample ID and press “Go”. The MiQLab ™ system offers excellent sensitivity, specificity and detection range and can return results in approximately two hours. The unique open access feature is designed for custom testing so end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including availability of funds, results of fundraising efforts, success of technology development efforts, cost of purchasing critical parts, instrument performance, market acceptance of technology , regulatory acceptance and licensing issues – which could cause issues actual results differ materially from the Company’s expectations as disclosed in Company documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
Corporate Contact: Gail Winslow Director of Corporate Marketing [email protected] 978.482.6237 [email protected] 800.215.1824